Enhancement of specific cellular immune response induced by DNA vaccines encoding PML-RARα and hIL-2 genes

Hematology

Volumn 15, Issue 2, 2010, Pages 88-95

  Cen, Dongzhi ^a,b   Hu, Gang ^a,c   Zhou, Yubing ^a   Yang, Lijian ^a   Chen, Shaohua ^a   Schmidt, Christian A ^d   Li, Yangqiu ^a,e  

^a MEDICAL COLLEGE OF JINAN UNIVERSITY   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c People's Hospital of Huidong   (China)

^d UNIVERSITY OF GREIFSWALD   (Germany)

^e JINAN UNIVERSITY   (China)

Author keywords

APL; Dna vaccine; Human interleukin 2; PML RAR

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; INTERLEUKIN 2; PROMYELOCYTIC LEUKEMIA PROTEIN; RETINOIC ACID RECEPTOR ALPHA; T LYMPHOCYTE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DNA IMMUNIZATION; GENE EXPRESSION; GENE REARRANGEMENT; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; SPLEEN CELL; THYMOCYTE; TUMOR IMMUNITY;

ANIMALS; CELL LINE, TUMOR; CYTOTOXICITY TESTS, IMMUNOLOGIC; GENE REARRANGEMENT, T-LYMPHOCYTE; GENETIC VECTORS; HUMANS; IMMUNITY, CELLULAR; IMMUNIZATION; INJECTIONS, INTRAMUSCULAR; INTERFERON-GAMMA; INTERLEUKIN-2; MALE; MICE; MICE, INBRED BALB C; MUSCLE, SKELETAL; ONCOGENE PROTEINS, FUSION; RANDOM ALLOCATION; RECOMBINANT FUSION PROTEINS; SPLEEN; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, DNA;

EID: 77952185345     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/102453310X125833470096589073     Document Type: Article

References (31)

1. Perego RA, Marenco P, Bianchi C et al. PML/RAR alpha transcripts monitored by polymerase chain reaction in acute promyelocytic leukemia during complete remission relapse and after bone marrow transplantation. Leukemia 1996; 10: 207-212.
2. Osman Y, Takahashi M, Zheng Z et al. Dendritic cells stimulate the expansion of PML-RAR alpha specific cytotoxic T-lymphocytes: its applicability for antileukemia immunotherapy. Clin. Cancer Res 1999; 18: 485-492.
3. Puccetti E, Ruthardt M. Acute promyelocytic leukemia: PML/ RARalpha and the leukemic stem cell. Leukemia 2004; 18: 1169-1175.
4. Li Y, Chen S, Yang L et al. Clonal expanded TCR Vbeta T cells in patients with APL. Hematology 2005; 10: 135-139.
5. Gambacorti-Passerini C, Grignani F, Arienti F, Pandolfi PP, Pelicci PG, Parmiani G. Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein pml/RAR alpha present in acute promyelocytic leukemia cells. Blood 1993; 81: 1369-1375.
6. Duncan C, Roddie H. Dendritic cell vaccines in acute leukaemia. Best Pract Res Clin Haematol 2008; 21: 521-541.
7. Dunussi-Joannopoulos K. Malignancy: gene therapy vaccines in acute myeloid leukemia: a need for clinical evaluation. Hematology 2000; 5: 103-115.
8. Tonheim TC, Bogwald J, Dalmo RA. What happens to the DNA vaccine in fish? A review of current knowledge. Fish Shellfish Immunol 2008; 25: 1-18.
9. Johnson LE, Frye TP, Chinnasamy N, Chinnasamy D, McNeel DG. Plasmid DNA vaccine encoding prostatic acid phosphatase is effective in eliciting autologous antigen-specific CD8z T cells. Cancer Immunol Immunother 2007; 56: 885-895.
10. Timmerman JM, Singh G, Hermanson G et al. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. Cancer Res 2002; 62: 5845-5852.
11. Bocchia M, Wentworth PA, Southwood S et al. Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules. Blood 1995; 85: 2680-2684.
12. Dermime S, Bertazzoli C, Marchesi E et al. Lack of T-cellmediated recognition of the fusion region of the pml/RAR-alpha hybrid protein by lymphocytes of acute promyelocytic leukemia patients. Clin Cancer Res 1996; 2: 593-600.
13. Yu M, Finn OJ. DNA vaccines for cancer too. Cancer Immunol Immunother 2006; 55: 119-130.
14. Padua RA, Larghero J, Robin M et al. PML-RARA-targeted DNA vaccine induces protective immunity in a mouse model of leukemia. Nat Med 2003; 9: 1413-1417.
15. Belakova J, Horynova M, Krupka M, Weigl E, Raska M. DNA vaccines: are they still just a powerful tool for the future? Arch Immunol Ther Exp (Warsz) 2007; 55: 387-398.
16. Mencoboni MP, Tredici S, Varaldo M et al. Chemoimmunotherapy with low dose vinorelbine and interleukin-2 in treatment of patients with metastatic renal cell carcinoma. Neoplasma 2006; 53: 333-336.
17. Feurino LW, Fisher WE, Bharadwaj U, Yao Q, Chen C, Li M. Current update of cytokines in pancreatic cancer: pathogenic mechanisms, clinical indication, and therapeutic values. Cancer Invest 2006; 24: 696-703.
18. Stein AS, O'Donnell MR, Slovak ML et al. Interleukin-2 after autologous stem-cell transplantation for adult patients with acute myeloid leukemia in first complete remission. J Clin Oncol 2003; 21: 615-623.
19. Sievers EL, Lange BJ, Sondel PM et al. Children's cancer group trials of interleukin-2 therapy to prevent relapse of acute myelogenous leukemia. Cancer J Sci Am 2000; 6(Suppl 1): S39-44.
20. Greenland JR, Letvin NL. Chemical adjuvants for plasmid DNA vaccines. Vaccine 2007; 25: 3731-3741.
21. Huehn J, Siegmund K, Lehmann JC et al. Developmental stage, phenotype, and migration distinguish naive-and effector/ memory-like CD4z regulatory T cells. J Exp Med 2004; 199: 303-313.
22. Li Y, Chen S, Yang L et al. TRAV and TRBV repertoire, clonality and the proliferative history of umbilical cord blood T cells. Transplant Immunol 2007; 18: 151
23. Guinn BA, Mohamedali A, Thomas NS, Mills KI. Immunotherapy of myeloid leukaemia. Cancer Immunol Immunother 2007; 56: 943-957.
24. Waldmann TA. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol 2006; 6: 595-601.
25. Mekhail T, Wood L, Bukowski R. Interleukin-2 in cancer therapy: uses and optimum management of adverse effects. BioDrugs 2000; 14: 299-318.
26. Niethammer AG, Xiang R, Ruehlmann JM et al. Targeted interleukin 2 therapy enhances protective immunity induced by an autologous oral DNA vaccine against murine melanoma. Cancer Res 2001; 61: 6178-6184.
27. Ribeiro RM, Perelson AS. Determining thymic output quantitatively: using models to interpret experimental T-cell receptor excision circle (TREC) data. Immunol Rev 2007; 216: 21-34.
28. Bertho JM, Demarquay C, Moulian N, van der Meeren A, Berrih-Aknin S, Gourmelon P. Phenotypic and immunohistological analyses of the human adult thymus: evidence for an active thymus during adult life. Cell Immunol 1997; 179: 30-40.
29. Lalezari JP, Beal JA, Ruane PJ et al. Low-dose daily subcutaneous interleukin-2 in combination with highly active antiretroviral therapy in HIVz patients: a randomized controlled trial. HIV Clin Trials 2000; 1: 1-15.
30. Marchetti G, Meroni L, Molteni C et al. Interleukin-2 immunotherapy exerts a differential effect on CD4 and CD8 T cell dynamics. AIDS 2004; 18: 211-216.
31. Marchetti G, Meroni L, Varchetta S et al. Low-dose prolonged intermittent interleukin-2 adjuvant therapy: results of a randomized trial among human immunodeficiency virus-positive patients with advanced immune impairment. J Infect Dis 2002; 186: 606-616.